A North American distribution center for generic drug maker Teva, one of the largest developments on the horizon for Philadelphia, is now on hold. George Chressanthis, who directs the Center for Healthcare Research and Management at Temple's Fox School of Business, calls the state of the pharmaceutical industry "tumultuous," with drug companies releasing fewer new products. "That's important for generic companies because generics rely on new branded drugs to come onto market, which eventually then lose patent expiration and then generics come in," he said.